Migraine Headache Clinical Trial
Official title:
A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache
Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).
Study 20170703 is a phase 4, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the safety and efficacy of erenumab against placebo in a CM population with MOH and prior history of treatment failure. Participants will be enrolled based on fulfilment of the International Classification of Headache Disorders, 3rd Edition (ICHD-3) CM and MOH criteria and will not be advised to early discontinue acute medication. Participants who successfully complete the 24-week double-blind treatment period (DBTP) of the study will be offered an opportunity to continue in an open-label treatment period (OLTP) of 28-weeks duration. Participants who received erenumab treatment during the DBTP will continue to receive the same erenumab dose during the OLTP. Participants who received placebo during the DBTP will be allocated in a 1:1 ratio to receive either erenumab 70 mg or 140 mg SC QM during the OLTP. All participants will remain blinded to their original DBTP treatment assignment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
| Not yet recruiting |
NCT05943457 -
Vitamin K2 Supplementation in Adult Episodic Migraine
|
N/A | |
| Completed |
NCT01211145 -
Zomig - Treatment of Acute Migraine Headache in Adolescents
|
Phase 4 | |
| Completed |
NCT00530517 -
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
|
Phase 2 | |
| Completed |
NCT00898677 -
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
|
Phase 3 | |
| Withdrawn |
NCT02706015 -
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
|
Phase 3 | |
| Terminated |
NCT02375789 -
Intranasal Cooling for Symptomatic Relief of Migraine
|
N/A | |
| Completed |
NCT02518464 -
Ticagrelor Therapy for RefrACTORy Migraine Study
|
Phase 4 | |
| Terminated |
NCT00391755 -
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
|
Phase 4 | |
| Completed |
NCT03401346 -
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
|
Phase 1 | |
| Completed |
NCT05085483 -
Ketone for Migraine Prevention
|
N/A | |
| Completed |
NCT01604785 -
Low-dose Propofol for Pediatric Migraine
|
Phase 2/Phase 3 | |
| Terminated |
NCT00804973 -
Study in Participants With Acute Migraines Headaches
|
Phase 2 | |
| Completed |
NCT03341689 -
Psilocybin for the Treatment of Migraine Headache
|
Phase 1 | |
| Completed |
NCT01630044 -
Neurostimulation Device for Treatment of Migraine Headache
|
N/A | |
| Active, not recruiting |
NCT00285402 -
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
|
Phase 2 | |
| Completed |
NCT00203255 -
Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache
|
N/A | |
| Recruiting |
NCT06046508 -
Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
|
||
| Active, not recruiting |
NCT04584762 -
Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine
|
N/A | |
| Terminated |
NCT03099070 -
Acute Stress Response in Migraine Sufferers
|
N/A |